GLOBAL
We Work to Give Medical Professionals the Tools They Need
Alnylam is committed to supporting and partnering with the healthcare community, across many disease areas. This includes providing information on our research and treatments in development.
Acting “Upstream” of Today’s Medicines
With investigational RNAi therapeutics, we believe it may be possible to block the production of disease-causing proteins before they are made.
OUR
PIPELINE
Late Stage
Learn more about our investigational therapies in hereditary ATTR amyloidosis, hemophilia, acute hepatic porphyria, and primary hyperoxaluria type 1.
Alnylam Grant Information
Alnylam is committed to supporting the medical and scientific understanding of our therapeutic areas of interest for healthcare professionals. Additionally, we are committed to supporting educational programs and initiatives spearheaded by organizations focused on patient advocacy, community education and support, and other scientific efforts related to our therapeutic areas of interest.
The following are the available Request for Grant Proposals:
Consensus Guidelines on the Identification and Diagnosis of Porphyrias.
Differential Identification of Rare Causes of Motility Disorders (REGP 3a)
Educational Grant
To submit a request for funding related to a grant, please email your requests or inquiries to grants@alnylam.com. Grant requests should include, at a minimum*, the following:
-
A comprehensive proposal of the request
-
A detailed budget
*Please note that some grants have specific requirements
To submit a request for an Independent Medical Education (IME) activity, please visit www.alnylam.com/grants
Sponsorship
To submit a request for funding related to a sponsorship, please email your requests or inquiries to grants@alnylam.com. Sponsorship requests should include, at a minimum, the following:
-
Current agenda for the event (drafts are acceptable)
-
Sponsorship levels and benefits
-
W-9
Access to Investigational Medicines
Alnylam is dedicated to developing new therapies that have a positive impact on patient health, and to serving patients, patient families, and patient communities through education, empathy, and awareness. We understand that there are seriously ill patients who will not be eligible for our clinical trials and may not have options for alternative therapies, including investigational therapies in trials being conducted by other sponsors. In these circumstances, Alnylam will consider providing a requesting physician with pre-approval access to a specific Alnylam investigational medicine, for the treatment of an individual patient outside of a clinical trial, when certain conditions are met.
To read our statement on access to investigational medicines, click here.
APPROVED IN THE U.S.
Learn more about an FDA-approved treatment option available for patients in the U.S.
ALNYLAM ASSIST
Alnylam AssistTM helps patients access ONPATTRO® (patisiran) with personalized support.
ALNYLAM ACT
Alnylam Act provides no-charge, independent genetic testing and counseling to individuals in the US and Canada who may have hATTR amyloidosis, acute hepatic porphyria, or primary hyperoxaluria type 1 (PH1).
ACUTE HEPATIC PORPHYRIA (AHP)
Learn more about the signs and symptoms of AHP, and how to guide your patients to a clear diagnosis.
